The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology
Language English Country England, Great Britain Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
30475219
DOI
10.1530/joe-18-0532
PII: JOE-18-0532.R1
Knihovny.cz E-resources
- Keywords
- Alzheimer’s disease pathology, anorexigenic neuropeptides, experimental rodent models, leptin,
- MeSH
- Alzheimer Disease metabolism prevention & control MeSH
- Appetite Depressants metabolism pharmacology MeSH
- Energy Metabolism drug effects MeSH
- Homeostasis drug effects MeSH
- Pyrrolidonecarboxylic Acid analogs & derivatives metabolism pharmacology MeSH
- Leptin metabolism MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Neuroprotective Agents pharmacology MeSH
- Oligopeptides metabolism pharmacology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Appetite Depressants MeSH
- Pyrrolidonecarboxylic Acid MeSH
- Leptin MeSH
- Neuroprotective Agents MeSH
- Oligopeptides MeSH
- pyroglutamyl-histidyl-glycine MeSH Browser
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the elderly population. Numerous epidemiological and experimental studies have demonstrated that patients who suffer from obesity or type 2 diabetes mellitus have a higher risk of cognitive dysfunction and AD. Several recent studies demonstrated that food intake-lowering (anorexigenic) peptides have the potential to improve metabolic disorders and that they may also potentially be useful in the treatment of neurodegenerative diseases. In this review, the neuroprotective effects of anorexigenic peptides of both peripheral and central origins are discussed. Moreover, the role of leptin as a key modulator of energy homeostasis is discussed in relation to its interaction with anorexigenic peptides and their analogs in AD-like pathology. Although there is no perfect experimental model of human AD pathology, animal studies have already proven that anorexigenic peptides exhibit neuroprotective properties. This phenomenon is extremely important for the potential development of new drugs in view of the aging of the human population and of the significantly increasing incidence of AD.
References provided by Crossref.org
An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis
Obesity, Cardiovascular and Neurodegenerative Diseases: Potential Common Mechanisms
Prolactin-Releasing Peptide: Physiological and Pharmacological Properties
